case_images: PMC10323425_01
case_images: The using of ICI drugs.
case_images: fimmu-14-1114994-g001.jpg
case_images: PMC10323425_01_fimmu-14-1114994-g001.jpg
case_images: f1
case_images: Chemotherapy with the R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin), and prednisone) regimen was administered on March 18, 2022, and cycle 8 penpulimab treatment was administered on March 23, 2022 ( Figure 1 ).
case_images: The Chest CT on April 3rd.
case_images: fimmu-14-1114994-g002.jpg
case_images: PMC10323425_01_fimmu-14-1114994-g002.jpg
case_images: f2
case_images: On April 3, the patient was admitted to the Respiratory Department for persistent cough and dyspnea since Mar 30, 2022, and  Figure 2  shows the patient's CT.
case_images: The Chest CT on April 7th.
case_images: fimmu-14-1114994-g003.jpg
case_images: PMC10323425_01_fimmu-14-1114994-g003.jpg
case_images: f3
case_images: Broad-spectrum antibiotics were administered, and the patient was transferred to the intensive care unit on April 9, 2022, for the treatment of worsening dyspnea, increased pulmonary infiltrates ( Figure 3 ), and poor oxygenation index.
case_images: The Chest CT on April 11th.
case_images: fimmu-14-1114994-g004.jpg
case_images: PMC10323425_01_fimmu-14-1114994-g004.jpg
case_images: f4
case_images: Chest CT was repeated on April 11, 2022, for bilateral lung lesion absorption ( Figure 4 ).
case_images: The Chest CT on April 20th.
case_images: fimmu-14-1114994-g005.jpg
case_images: PMC10323425_01_fimmu-14-1114994-g005.jpg
case_images: f5
case_images: April 20, 2022, and a repeat CT indicated further absorption of bilateral lung lesions ( Figure 5 ), The hormone dose was reduced to prednisone 50 mg, and the patient was discharged with a weekly dose reduction of 5-10 mg ( Figure 6 ).
case_images: The using of hormone.
case_images: fimmu-14-1114994-g006.jpg
case_images: PMC10323425_01_fimmu-14-1114994-g006.jpg
case_images: f6
case_images: April 20, 2022, and a repeat CT indicated further absorption of bilateral lung lesions ( Figure 5 ), The hormone dose was reduced to prednisone 50 mg, and the patient was discharged with a weekly dose reduction of 5-10 mg ( Figure 6 ).
case_images: The Chest CT on May 25th.
case_images: fimmu-14-1114994-g007.jpg
case_images: PMC10323425_01_fimmu-14-1114994-g007.jpg
case_images: f7
case_images: As of May 25, 2022, the patient had no restrictions in daily activities, respiratory distress, or other manifestations, and the CT was reviewed in the outpatient clinic ( Figure 7 ). At the follow-up on August 22, 2022, the patient underwent a repeat CT as an outpatient, which showed a visible occupying lesion in the left lung ( Figure 8 ).
case_images: The Chest CT on August 22nd.
case_images: fimmu-14-1114994-g008.jpg
case_images: PMC10323425_01_fimmu-14-1114994-g008.jpg
case_images: f8
case_images: As of May 25, 2022, the patient had no restrictions in daily activities, respiratory distress, or other manifestations, and the CT was reviewed in the outpatient clinic ( Figure 7 ). At the follow-up on August 22, 2022, the patient underwent a repeat CT as an outpatient, which showed a visible occupying lesion in the left lung ( Figure 8 ).